At present, ∼200 million people worldwide are infected with hepatitis C virus (HCV). Current estimates indicate that 30% of infected individuals spontaneously resolve their infections [1] . Both resolution and protection correlate with the presence of HCV-specific T cell responses [2] [3] [4] . Of the 70% of HCV-infected individuals whose infection progresses to chronic HCV infection, pegylated interferon (IFN)-a and ribavirin enable ∼50% to sustain virological responses after treatment is discontinued [5, 6] . The roles that HCV-specific T cell responses and IFN-a play highlight the importance
of understanding dendritic cell (DC) function during HCV infection since myeloid DCs are required for priming T cells in vivo and since plasmacytoid DCs are the principle cell type responsible for endogenous IFN-a production [7] .
Although initial reports have shown impaired maturation and allostimulation of monocyte-derived DCs from patients with chronic HCV infection [8] [9] [10] , our work in humans and recent studies in chimpanzees do not support these findings [11, 12] . Nonetheless, one caveat is that these studies focused on in vitro-derived DCs. To evaluate native circulating DCs, we took advantage of the ability to purify myeloid DCs, which make up 0.5%-1.0% of the peripheral blood mononuclear cells (PBMCs) and can be purified on the basis of expression of blood dendritic cell antigen (BDCA)-1 and lack of expression of CD19 [13] .
The other DC subset of interest in circulating blood is the plasmacytoid DC. Originally defined as IFN-aproducing cells [14] , plasmacytoid DCs can be distinguished on the basis of surface expression of CD123, BDCA-2, or BDCA-4 [13] . Although plasmacytoid DCs exist at very low frequencies (0.2%-0.5% of PBMCs), cytometric analysis permits simultaneous gating of cell populations of interest and determination of functional activity (e.g., production of IFN-a) [15] . Here, we provide a careful analysis of both cell populations in patients with chronic HCV infection and conclude that there are no phenotypic or functional defects in the myeloid DC subset and no decrease in the amount of IFN-a produced on a per-plasmacytoid DC basis. (table 1) . Samples were also collected from 17 healthy, non-HCV-infected individuals. Sustained virological responders (SVRs) ( ) were HCV RNA negative 6 months after n p 6 completion of pegylated IFN/ribavirin therapy. PBMCs were also collected from patients with non-HCV liver disease ( ), including hepatitis B, granulomatous hepatitis, and n p 7 cirrhosis.
PATIENTS, MATERIALS, AND METHODS

Patients
Isolation and preparation of cells. PBMCs were isolated from whole blood by sedimentation over Ficoll-Hypaque (Amersham Pharmacia). Myeloid DCs were isolated by use of a BDCA-1 Isolation Kit (Miltenyi Biotec). Mature myeloid DC cultures were generated after purification with 50 ng/mL tumor necrosis factor (TNF)-a (AlexisBiochemicals) and 0.1 mmol/L prostaglandin E 2 (Sigma) for 36-48 h [17] . the average maximal proliferation achieved when mature myeloid DCs were used at a ratio of 30 T cells:1 DC. In all cases, maximal proliferation was 1100,000 cpm/ T cells. used to label plasmacytoid DCs in the PBMC fraction, after stimulation. To measure the quantity of total IFN-a produced, supernatants from parallel cultures were collected after 24 or 48 h and were assayed by use of a human IFN-a ELISA (PBL Laboratories). Importantly, all PBMC samples used for IFN-a assays were freshly prepared and used within 12 h, since IFNa production was significantly affected by freeze-thaw (110-fold decrease in IFN-a production in parallel samples). IFNa production was normalized per plasmacytoid DC on the basis of the percentage of plasmacytoid DCs in the PBMC fraction.
Statistics. Two-tailed nonparametric comparisons (MannWhitney U test) were used to calculate P values for differences in numbers of myeloid DCs and plasmacytoid DCs, as well as total IFN-a production by PBMCs, since this method allows for generation of data with a non-Gaussian distribution. P values for normalized data were calculated by use of a 2-tailed parametric comparison (Welch-corrected unpaired t test).
RESULTS AND DISCUSSION
To enumerate the different hematopoetic lineages in PBMCs, we used flow-cytometric analysis. By use of the scatter properties of the cells (size and granularity), as well as staining with anti-CD19 and anti-CD14 MAbs, it was possible to enumerate B cells and monocytes ( figure 1A ). Cells were simultaneously labeled with anti-CD1c and anti-BDCA-2 MAbs, thus allowing selection of CD19 Ϫ cells and enumeration of the BDCA-1 + myeloid DC and the BDCA-2 + plasmacytoid DC populations ( figure 1A ). Absolute numbers of the respective cell populations were normalized to the total number of PBMCs collected, to obtain the relative percentage of each cell type (figure 1B). De-spite the greater heterogeneity in the percentage of B cells in patients with HCV infection seen here as well as in previous studies [18] , we observed no statistical difference in the median percentage of B cells or monocytes. We did, however, reveal a small but marginally significant difference in the percentage of myeloid DCs between patients with chronic HCV infection and healthy, non-HCV-infected individuals (0.62 vs. 0.83; P p .05). In addition, the data indicate a reduction in the percentage of plasmacytoid DCs in patients with chronic HCV infection (0.11 vs. 0.34;
), compared with those from healthy, non-P p .004 HCV-infected individuals. Although potentially important to disease progression, this observation is not specific for chronic HCV infection. We found lower numbers of DCs in SVRs (n p 6) and patients with non-HCV liver disease ( ). Low n p 7 numbers of plasmacytoid DCs have also been found in patients with HIV/AIDS [19] .
To isolate myeloid DCs and evaluate their functional characteristics, large numbers of PBMCs were collected by leukapheresis from 4 patients with chronic HCV infection. figure 2A ). After exposure of myeloid DCs to TNF-a, up-regulation of the maturation markers CD25, CD40, CD83, CD86, and HLA-DR was observed ( figure 2A ). This up-regulation corresponded with a functional change in allostimulatory potential, which is also characteristic of mature DCs ( figure 2B ). Of note, the phenotype and priming capacity of myeloid DCs from patients with chronic HCV infection were equivalent to the capacities of those from healthy, non-HCVinfected individuals (figure 2B).
We next addressed the function of plasmacytoid DCs from patients with chronic HCV infection. In humans, plasmacytoid DCs produce robust amounts of IFN-a after engagement of Toll-like receptor (TLR) 7 (a receptor for ssRNA) or TLR9 (a receptor for CpG motifs) [20] . We stimulated the PBMCs with live influenza virus or CpG-2216 and measured IFN-a production by ELISA ( figure 2C) . Notably, IFN-a production was lower in patients with chronic HCV infection than in healthy, non-HCV-infected individuals when PBMCs were stimulated with 50 HAU/mL influenza virus (3.9 vs. 12.3 ng/mL; P p .07) or CpG-2216 (4.9 vs. 26.1 ng/mL; ). However, when P p .04 normalized to the respective percentage of plasmacytoid DCs in the PBMC sample, the difference in IFN-a production was no longer statistically significant between patients with chronic HCV infection and healthy, non-HCV-infected individuals for either influenza virus (1.3 vs. 1.9 pg/mL) or CpG (2.0 vs. 2.9 pg/mL) ( figure 2D ). These findings suggest that, although lower in number, the plasmacytoid DCs are unimpaired in their production of IFN-a in response to TLR ligands.
To verify IFN-a production by plasmacytoid DCs from HCVinfected patients and to evaluate the percentage of IFN-a-producing plasmacytoid DCs, we assayed stimulated PBMCs for intracellular IFN-a by flow-cytometric analysis, after 5 h of stimulation with influenza virus or CpG-2216 ( figure 2E ). Only the plasmacytoid DCs produced measurable IFN-a under these conditions, and, by gating this population, we could assess the percentage of IFN-a-producing plasmacytoid DCs ( figure 2E ).
The data indicate that, despite the decreased percentage of plasmacytoid DCs in the circulating blood, plasmacytoid DCs respond equally well to influenza virus and CpG motifs on a percell basis ( figure 2D-2F ).
The role that DCs play in chronic HCV infection has been controversial. Although several studies initially reported dysfunction in monocyte-derived DCs [8] [9] [10] , our prior work argues for fully functional DCs in patients with chronic HCV infection [11] . This controversy extends to circulating myeloid DCs; however, no direct mechanism for the putative DC dysfunction has been demonstrated [21, 22] . Furthermore, these reports do not account for the HCV specificity of the immune defect. Similar to those of several recent studies, our data support the finding of lower percentages of myeloid DCs and plasmacytoid DCs in PBMCs from patients with chronic HCV infection [22, 23] . However, on the basis of the isolation and characterization of myeloid DCs ( figure 2A and 2B) , as well as the single-cell analysis of plasmacytoid DCs ( figure 2D-F) , we conclude that there is no global dysfunction in these cell populations in vivo as a result of chronic HCV infection. Moreover, these findings support the use of autologous DCs as an effective strategy for HCV immunotherapy [12] as well as provide a rationale for current strategies aimed at stimulating endogenous IFN-a production through the use of plasmacytoid DC-stimulating agents, such as CpG [24] .
